Business
INOVIO Reports Third Quarter 2020 Financial Results
Investor Call Today at 4:30 PM ET PLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Investor Call Today at 4:30 PM ET\n\n\nPLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended September 30, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a clinical program update for its DNA medicines portfolio. The live webcast and a replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx. \nINOVIO Third Quarter 2020 Highlights \nINOVIO has responded to the United States Food & Drug Administration (FDA) to address the questions related to the partial clinical hold on INOVIO's Investigational New Drug Application (IND) for the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800 Recent publication of preclinical data in npj Vaccines demonstrated INO-4800's ability to neutralize multiple newly prevalent mutant strains of the SARS-CoV-2 virus INOVIO added Thermo Fisher Scientific to its global manufacturing consortium to manufacture COVID-19 vaccine candidate INO-4800 INO-5401 glioblastoma (GBM) overall survival at 18 months (OS18) data selected for late-breaking presentation at the Society for Neuro-Oncology 2020 Annual Meeting on November 20, 2020 Completion of double-blind Phase 3 REVEAL 1 data collection for VGX-3100 has been impacted by the recent pandemic surge; data readout for primary CIN Phase 3 trial is expected in the first half of 2021 INO-3107, a DNA medicine candidate for treatment of recurrent respiratory papillomatosis (RRP), a rare, debilitating disease caused by human papillomavirus (HPV) infection, was granted Orphan Drug designation by the FDADr. J. Joseph Kim, INOVIO's President and CEO, said, \"INOVIO continues to focus on the development of our COVID-19 vaccine, INO-4800, as well as advancing our other core DNA medicine programs. We are committed to following the science – on a critically important mission to safely and diligently develop medicines to address the impact of COVID-19 and other infectio...